Patient experiences with liraglutide for obesity and binge eating disorder–A qualitative study
PLOS One · 31.10.2025 · 20 (10) · e0335806
DOI: 10.1371/journal.pone.0335806 ↗Kurz gefasst
Qualitative Studie in der Zeitschrift PLOS One, online erschienen am 31.10.2025. Verfasst von Ingrid Sørdal Følling und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, No…. Hauptthemen laut MEDLINE: Liraglutide, Binge-Eating Disorder, Obesity. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Obesity is a growing health concern and a known risk factor for binge eating disorder (BED). BED is characterized by episodes of overeating with a loss of control, often leading to psychological distress. In some cases, medication may be recommended to manage depressive symptoms and support weight loss. Liraglutide, a glucagon-like peptide-1 (GLP-1) analog, works by targeting the brain’s reward system to reduce psychological stress and enhance feelings of fullness. However, there is limited research on the use of liraglutide for patients with both obesity and BED. This qualitative study aimed to investigate how patients with these conditions experience treatment with liraglutide.
Methods
A qualitative design with individual semi-structured, in-depth interviews was employed. Eight informants aged 25–60 years were interviewed, and data were analyzed using systematic text condensation.
Results
Two main themes, each with three associated subthemes, emerged. The first main theme was: The role of food on the expression of BED , with subthemes: Food as an emotion regulator, Persistent thoughts on eating and dieting , and Emotional and situational triggers for binge eating . The second main theme was Experiences with liraglutide in managing BED , with subthemes: Meeting emotional and physical needs, Reducing thoughts about food , and Decreasing triggers for eating . The experiences with medication (main theme 2) influenced the expression of BED (main theme 1) as informants reported that liraglutide impacted their BED symptoms.
Discussion
Findings suggest that patients with obesity and BED found liraglutide helpful in addressing emotional and physical needs, enhancing emotional well-being, social interactions, and overall quality of life. Further qualitative research is needed to explore the long-term impact of liraglutide on emotional and behavioral changes in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.
- Centre for Obesity Research and Innovation, Clinic of Surgery, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.
- Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.
ORCID-Profile: Ingrid Sørdal Følling, Anne-Sofie Helvik
Zitieren
APA
Følling, I. S., Reigstad, S. L., Hyldmo, Å. A., & Helvik, A. S. (2025). Patient experiences with liraglutide for obesity and binge eating disorder–A qualitative study. PLOS One, 20(10), e0335806. https://doi.org/10.1371/journal.pone.0335806
Vancouver
Følling IS, Reigstad SL, Hyldmo ÅA, Helvik AS. Patient experiences with liraglutide for obesity and binge eating disorder–A qualitative study. PLOS One. 2025;20(10):e0335806. doi:10.1371/journal.pone.0335806
BibTeX
@article{Flling2025,
author = {Følling, Ingrid Sørdal and Reigstad, Stine Larsen and Hyldmo, Åsne Ask and Helvik, Anne-Sofie},
title = {Patient experiences with liraglutide for obesity and binge eating disorder–A qualitative study},
journal = {PLOS One},
year = {2025},
volume = {20},
number = {10},
pages = {e0335806},
doi = {10.1371/journal.pone.0335806}
}
EUVIMED